vp

ISSUE – Nov. 23 | Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19

Resilience, a new biopharmaceutical company backed by $800 million in financing from investors including ARCH Venture Partners and 8VC, has emerged from stealth to transform the way that drugs and therapies are manufactured in the U.S. Founded by ARCH Venture Partners  investor Robert Nelsen, National Resilience  Inc., which does business as Resilience was born out of Nelsen’s frustrations with the inept American response to the COVID-19 pandemic. According to a statement the company will invest heavily in developing new manufacturing technologies across cell and gene therapies, viral vectors, vaccines and proteins. [ Tech Crunch ]

Checkout 15K+ Venture Capital Data on our platform.

 

vp1 vp2